301 related articles for article (PubMed ID: 20561044)
1. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M
Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
[TBL] [Abstract][Full Text] [Related]
5. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Hao Q; Kanda M; Tani Y
BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
[TBL] [Abstract][Full Text] [Related]
9. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
[TBL] [Abstract][Full Text] [Related]
10. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
12. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
O'Connor PW; Goodman A; Willmer-Hulme AJ; Libonati MA; Metz L; Murray RS; Sheremata WA; Vollmer TL; Stone LA;
Neurology; 2004 Jun; 62(11):2038-43. PubMed ID: 15184611
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
14. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Cadavid D; Jurgensen S; Lee S
PLoS One; 2013; 8(1):e53297. PubMed ID: 23308186
[TBL] [Abstract][Full Text] [Related]
15. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
16. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE
Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
[TBL] [Abstract][Full Text] [Related]
18. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR
Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679
[TBL] [Abstract][Full Text] [Related]
20. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
